Cargando…
74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
INTRODUCTION: The objective was to describe the prevalence, types, and predictors of adverse events (AEs) in rheumatoid arthritis (RA) patients treated with infliximab and methotrexate in a daily clinical setting. METHODS: This was a prospective, multi-center, open-label, 74-week observational study...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911915/ https://www.ncbi.nlm.nih.gov/pubmed/20569501 http://dx.doi.org/10.1186/ar3058 |